• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cataract - Pipeline Review, H2 2012 Product Image

Cataract - Pipeline Review, H2 2012

  • Published: November 2012
  • 48 pages
  • Global Markets Direct

Cataract – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cataract - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cataract, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cataract. Cataract - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cataract.
- A review of the Cataract products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Cataract Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cataract 7
Cataract Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Cataract Therapeutics – Products under Development by Companies 13
Companies Involved in Cataract Therapeutics Development 14
R-Tech Ueno, Ltd. 14
NovaLead Pharma Pvt. Ltd. 15
Omeros Corporation 16
ESBATech AG 17
Laboratorios Sophia S.A. de C.V. 18
Cataract – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
VLD-01 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ESBA-105 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
dexamethasone acetate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MTP-131 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RTU-007 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GPR161 Antagonist - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PRO-155 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cataract Therapeutics – Drug Profile Updates 34
Cataract Therapeutics - Dormant Products 38
Cataract – Product Development Milestones 39
Featured News & Press Releases 39
Nov 29, 2011: Omeros Submits Paediatric Investigation Plan Letter Of Intent For OMS302 To European Medicines Agency 39
Oct 11, 2011: Omeros Announces First Patients Treated In Phase III Clinical Program Evaluating OMS302 39
May 19, 2011: Omeros Advances OMS302 Into Phase III Clinical Development Program 40
Mar 23, 2011: Omeros's Ophthalmology Product OMS302 Achieves Co-Primary Endpoints In Phase IIb Clinical Study 41
Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 41
Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 42
Aug 23, 2010: InSite Vision Initiates Phase I/II Clinical Study Of ISV-303 For Post-Surgical Ocular Pain And Swelling 43
Jul 27, 2010: Omeros Initiates Phase IIb Clinical Trial For OMS302 In Patients Undergoing Cataract Surgery 44
Jan 05, 2010: Icon Bioscience Initiates Phase II/III Pivotal Clinical Study Of Novel Ophthalmic Drug Candidate IBI-10090 45
Aug 11, 2009: Omeros Announces Positive Phase I/II Trial Results Of OMS302 For Use During Ophthalmologic Surgery 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Number of Products Under Development for Cataract, H2 2012 7
Products under Development for Cataract – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
R-Tech Ueno, Ltd., H2 2012 14
NovaLead Pharma Pvt. Ltd., H2 2012 15
Omeros Corporation, H2 2012 16
ESBATech AG, H2 2012 17
Laboratorios Sophia S.A. de C.V., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Cataract Therapeutics – Drug Profile Updates 34
Cataract Therapeutics – Dormant Products 38

List of Figures
Number of Products under Development for Cataract, H2 2012 7
Products under Development for Cataract – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos